German-based biopharmaceutical company, MorphoSys AG, is making significant strides in the development, discovery, and commercialization of therapeutic antibodies that help cancer and autoimmune disease patients. MorphoSys offers Tafasitamab, an antibody specifically designed for B cell malignancies such as diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma. The company is also currently developing therapies like Pelabresib, a tiny molecule to treat myelofibrosis; Felzartamab, an antibody directed against CD38 for the treatment of anti-PLA2R-positive membranous nephropathy; and CPI-0209, a small molecule used to suppress tumors by inhibiting EZH2 and EZH1. Additionally, MorphoSys is in the process of developing Gantenerumab, a particular type of antibody used for treating Alzheimer's diseases, and Otilimab, another antibody used for rheumatoid arthritis treatment. The company has entered into a licensing agreement with I-Mab Biopharma for developing and commercializing felzartamab in China, Taiwan, Hong Kong, and Macau. MorphoSys also has strategic alliances with LEO Pharma, a joint collaboration and license agreement with Incyte Corporation to develop and commercialize MorphoSys investigational compound tafasitamab. Additionally, it has a clinical collaboration with Incyte Corporation and Xencor, Inc. to investigate the effectiveness of tafasitamab, plamotamab, and lenalidomide in treating specific types of lymphoma. MorphoSys AG was founded in 1992 and has its headquarters in Planegg, Germany.
MorphoSys's ticker is MOR
The company's shares trade on the NASDAQ stock exchange
They are based in Planegg, Germany
There are 501-1000 employees working at MorphoSys
It is morphosys.com/en/home
MorphoSys is in the Healthcare sector
MorphoSys is in the Biotechnology industry
The following five companies are MorphoSys's industry peers: